-
Je něco špatně v tomto záznamu ?
HIV in pregnancy: Mother-to-child transmission, pharmacotherapy, and toxicity
L. Cerveny, P. Murthi, F. Staud
Jazyk angličtina Země Nizozemsko
Typ dokumentu časopisecké články, práce podpořená grantem, přehledy
NLK
Elsevier Open Access Journals
od 1995-01-25 do Před 1 rokem
Elsevier Open Archive Journals
od 1995-01-25 do Před 1 rokem
- MeSH
- antiretrovirové látky farmakologie MeSH
- HIV infekce farmakoterapie přenos MeSH
- infekční komplikace v těhotenství farmakoterapie virologie MeSH
- lidé MeSH
- placenta virologie MeSH
- těhotenství MeSH
- vertikální přenos infekce prevence a kontrola MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- těhotenství MeSH
- ženské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
An estimated 1.3 million pregnant women were living with HIV in 2018. HIV infection is associated with adverse pregnancy outcomes and all HIV-positive pregnant women, regardless of their clinical stage, should receive a combination of antiretroviral drugs to suppress maternal viral load and prevent vertical fetal infection. Although antiretroviral treatment in pregnant women has undoubtedly minimized mother-to-child transmission of HIV, several uncertainties remain. For example, while pregnancy is accompanied by changes in pharmacokinetic parameters, relevant data from clinical studies are lacking. Similarly, long-term adverse effects of exposure to antiretrovirals on fetuses have not been studied in detail. Here, we review current knowledge on HIV effects on the placenta and developing fetus, recommended antiretroviral regimens, and pharmacokinetic considerations with particular focus on placental transport. We also discuss recent advances in antiretroviral research and potential effects of antiretroviral treatment on placental/fetal development and programming.
Department of Obstetrics and Gynaecology The University of Melbourne Parkville Victoria Australia
Hudson Institute of Medical Research The Ritchie Centre Clayton Victoria Australia
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22003531
- 003
- CZ-PrNML
- 005
- 20220127150129.0
- 007
- ta
- 008
- 220113s2021 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.bbadis.2021.166206 $2 doi
- 035 __
- $a (PubMed)34197912
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Cerveny, Lukas $u Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic
- 245 10
- $a HIV in pregnancy: Mother-to-child transmission, pharmacotherapy, and toxicity / $c L. Cerveny, P. Murthi, F. Staud
- 520 9_
- $a An estimated 1.3 million pregnant women were living with HIV in 2018. HIV infection is associated with adverse pregnancy outcomes and all HIV-positive pregnant women, regardless of their clinical stage, should receive a combination of antiretroviral drugs to suppress maternal viral load and prevent vertical fetal infection. Although antiretroviral treatment in pregnant women has undoubtedly minimized mother-to-child transmission of HIV, several uncertainties remain. For example, while pregnancy is accompanied by changes in pharmacokinetic parameters, relevant data from clinical studies are lacking. Similarly, long-term adverse effects of exposure to antiretrovirals on fetuses have not been studied in detail. Here, we review current knowledge on HIV effects on the placenta and developing fetus, recommended antiretroviral regimens, and pharmacokinetic considerations with particular focus on placental transport. We also discuss recent advances in antiretroviral research and potential effects of antiretroviral treatment on placental/fetal development and programming.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a antiretrovirové látky $x farmakologie $7 D044966
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a HIV infekce $x farmakoterapie $x přenos $7 D015658
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a vertikální přenos infekce $x prevence a kontrola $7 D018445
- 650 _2
- $a placenta $x virologie $7 D010920
- 650 _2
- $a těhotenství $7 D011247
- 650 _2
- $a infekční komplikace v těhotenství $x farmakoterapie $x virologie $7 D011251
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Murthi, Padma $u Department of Medicine, School of Clinical Sciences, and Department of Pharmacology, Monash Biomedicine Discovery Institute Monash University, Clayton, Victoria, Australia; Hudson Institute of Medical Research, The Ritchie Centre, Clayton, Victoria, Australia; Department of Obstetrics and Gynaecology, The University of Melbourne, Parkville, Victoria, Australia
- 700 1_
- $a Staud, Frantisek $u Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic. Electronic address: frantisek.staud@faf.cuni.cz
- 773 0_
- $w MED00000539 $t Biochimica et biophysica acta. Molecular basis of disease $x 1879-260X $g Roč. 1867, č. 10 (2021), s. 166206
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34197912 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220113 $b ABA008
- 991 __
- $a 20220127150126 $b ABA008
- 999 __
- $a ok $b bmc $g 1751093 $s 1154680
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 1867 $c 10 $d 166206 $e 20210629 $i 1879-260X $m Biochimica et biophysica acta. Molecular basis of disease $n Biochim Biophys Acta $x MED00000539
- LZP __
- $a Pubmed-20220113
